PROSTASCINT is the first monoclonal antibody-based agent that targets prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. The study that supports its use, “Capromab pendetide (ProstaScint) imaging with central abdominal uptake: poor outcomes for prostate cancer patients,” by Haseman, et al., was presented at the 2007 Annual Meeting of the American Urological Association taking place May 19-24, 2007 in Anaheim, California. PROSTASCINT consists of Cytogen’s proprietary PSMA-targeting monoclonal antibody, 7E11-C5, linked to the imaging radioisotope Indium-111. By targeting PSMA, the PROSTASCINT molecular imaging procedure can detect the extent and spread of prostate cancer using a standard gamma camera.
Emerging data from several sources using the superimposition, or fusion, of the PROSTASCINT functional study upon an anatomic image such as Computed Tomography (CT) Imaging or Magnetic Resonance Imaging (MRI), have generated renewed interest in the clinical value of PROSTASCINT imaging. In January 2007, the National Comprehensive Cancer Network, or NCCN, updated its clinical practice guidelines and expanded PROSTASCINT’s role to include recurrent disease. The expanded NCCN guidelines reflect the growing awareness of the potential for PROSTASCINT fusion imaging to assess disease and plan individualized treatment regimens. ProstaScint scans are US Food and Drug Administration approved for pretreatment evaluation of metastatic disease in high-risk patients. They are also approved for post-prostatectomy assessment of recurrent disease in patients with a rising prostate-specific antigen level.
Schettino CJ, Kamer EL, Noz ME, et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR. 2004; 183:519-524.
Wong, Terence Z., Turkington, Timothy G., Polascik, Thomas J., Coleman, R. Edward
ProstaScint (Capromab Pendetide) Imaging Using Hybrid Gamma Camera-CT Technology
Am. J. Roentgenol. 2005 184: 676-680
Rodney J Ellis, Edward Kim, Ryan FoorRole of ProstaScint® for brachytherapy in localized prostate adenocarcinoma Expert Review of Molecular Diagnostics
July 2004, Vol. 4, No. 4, Pages 435-441